VC Deals Analysis: Asia Investors Pour Money Into Grail And May's Other Big Deals
Asian investors' unrelenting pursuit of medtech ventures continued to crescendo in May. The participants in the largest round so far this year, the $300m series C by Illumina spin-out Grail, are all China-based funds.
You may also be interested in...
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
A sub-analysis of the Circulating Cell-free Genome Atlas study show Grail's genome-sequencing technology may be able to detect early-stage lung cancer through DNA signals in the blood.
Venture financing activity hit the ground running in 2018 after a bumper haul of mega-raises brought the total deal value for January close to $1bn.